Improving leukemia therapy with targeted treatment approaches (Meyer lab)
![.](/fileadmin/_processed_/f/2/csm_iStock-leuka__mie_1000x500_bd3e5d2ed4.jpg?1631775534)
In chronic leukemias, blocking the overactive kinase JAK2 by a targeted therapy approach is only mitigating the patients’ symptoms, but cannot truly change the course of the disease. A study by the University of Basel has shown that it may be possible to improve the therapeutic effects by additionally inhibiting a specific signaling pathway. The results are so convincing that they are already being incorporated into clinical studies in a “bench-to-bedside” approach.